Oral Omega 3 GA. A phase II in subjects with geographic atrophy secondary to AMD 26/03/2013
A phase II, randomized, double masked clinical trial to establish the safety and efficacy of high oral doses of Omega-3 in patients with geographic atrophy secondary to dry age-related macular degeneration.
Key inclusion criteria
Patients with geographic atrophy secondary to dry age-related macular degeneration.
The objectives of this study are to evaluate the safety and efficacy of High-Dose Oral Omega 3 on the Photoreceptors/Retinal Pigment Epithelium/Bruch’s membrane complex in subjects with geographic atrophy secondary to age-related macular degeneration and to evaluate whether improvement in visual function occurs and progression to advanced stages of AMD is delayed.
If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155
Our team of professionals will answer you as soon as possible and we will assess whether you are eligible.
Доктор Jordi Monés, M.D., Ph.D.
Номер лицензии COMB: 22.838
Доктор Медицины и Хирургии
Специалист по Офтальмологии
Специалист по лечению Сетчатки, Макулы и Стекловидного тела